Cameron CE marks subcutaneous implantable defibrillator
This article was originally published in Clinica
Executive Summary
Cameron Health has CE marked its subcutaneous implantable defibrillator (S-ICD) device, a minimally-invasive system for use in patients at risk of sudden cardiac arrest. The system is entirely subcutaneous, with no leads in or on the heart, and imaging is not required to aid its placement, San Clemente, California-based Cameron claims. Surgical placement and presence of ICD leads within patients' hearts are associated with a significant proportion of the complications seen with the devices. Market launch in selected countries is due to begin this summer.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?